Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540423 | 0.87 | EPHX1 (0.57) | L3MBTL1LMNAMAPTALDH1A1HPGD | |
| SCHEMBL9070025 | 0.86 | L3MBTL1 (1.00) | L3MBTL1LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL11932743 | 0.81 | EPHX1 (0.65) | L3MBTL1MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL8198601 | 0.80 | KDM4E (0.76) | L3MBTL1LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4077586 | 0.79 | L3MBTL1 (0.84) | L3MBTL1LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13348937 | 0.78 | MAPT (0.56) | L3MBTL1SMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL4483811 | 0.78 | LMNA (0.72) | L3MBTL1LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL11163223 | 0.77 | EPHX1 (0.56) | L3MBTL1SMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL8945238 | 0.77 | NPSR1 (0.62) | LMNASMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL6118209 | 0.75 | EPHX1 (0.78) | L3MBTL1LMNAMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-7652019-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an antioxidant probucol; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7638520-B2 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | SMITHKLINE BEECHAM P.L.C. | 2009-07-02 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1686119-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1603881-A2 | SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY | Replidyne, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004078119-A2 | SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2000071524-A1 | 2-NH-PYRIDONES AND PYRIMIDONES AS MRS INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170877-A1 | 5,6-Trimethylenepyrimidin-4-one compounds | PLA2G4A, PLA2G4B, PLA2G1B | L3MBTL1 3417/4885LMNA 521/4885SMN1; SMN2 2914/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | L3MBTL1 3446/4885LMNA 2459/4885SMN1; SMN2 3746/4885 |
| US-20150045375-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | L3MBTL1 3707/4885LMNA 872/4885SMN1; SMN2 3960/4885 |
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | L3MBTL1 3707/4885LMNA 872/4885SMN1; SMN2 3960/4885 |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | L3MBTL1 2313/4885LMNA 694/4885SMN1; SMN2 4043/4885 |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | PLA2G7, PLAT, PLA2G1B | L3MBTL1 2733/4885LMNA 690/4885SMN1; SMN2 2858/4885 |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | L3MBTL1 3417/4885LMNA 521/4885SMN1; SMN2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.